• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study.

作者信息

Botzenhardt Sebastian, Felisi Mariagrazia, Bonifazi Donato, Del Vecchio Giovanni C, Putti Maria C, Kattamis Antonis, Ceci Adriana, Wong Ian C K, Neubert Antje

机构信息

Department of Paediatrics and Adolescent Medicine, Faculty of Medicine, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Erlangen, Germany.

Consorzio per Valutazioni Biologiche e Farmacologiche, Pavia, Italy.

出版信息

Haematologica. 2018 Jan;103(1):e1-e4. doi: 10.3324/haematol.2017.176065. Epub 2017 Oct 27.

DOI:10.3324/haematol.2017.176065
PMID:29079595
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5777195/
Abstract
摘要

相似文献

1
Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study.地中海地区重型β地中海贫血患儿去铁酮治疗的长期安全性：DEEP-3多中心观察性安全性研究
Haematologica. 2018 Jan;103(1):e1-e4. doi: 10.3324/haematol.2017.176065. Epub 2017 Oct 27.
2
The Role of Deferiprone in Iron Chelation.去铁酮在铁螯合中的作用。
N Engl J Med. 2018 Nov 29;379(22):2140-2150. doi: 10.1056/NEJMra1800219.
3
Prospective CMR Survey in Children With Thalassemia Major: Insights From a National Network.重度地中海贫血患儿的前瞻性心脏磁共振成像调查：来自一个全国性网络的见解
JACC Cardiovasc Imaging. 2020 May;13(5):1284-1286. doi: 10.1016/j.jcmg.2019.12.015. Epub 2020 Feb 12.
4
Deferiprone-induced seizures in a patient with β-thalassemia major.去铁酮诱发重型β地中海贫血患者癫痫发作。
Blood Cells Mol Dis. 2013 Aug;51(2):94-5. doi: 10.1016/j.bcmd.2013.03.002. Epub 2013 Apr 12.
5
A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.对重型β地中海贫血铁过载患者使用地拉罗司进行的15年随访。
Br J Haematol. 2020 Nov;191(3):e81-e83. doi: 10.1111/bjh.17035. Epub 2020 Sep 18.
6
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.β-地中海贫血患者螯合治疗相关并发症的临床监测与管理。
Expert Rev Hematol. 2016;9(2):151-68. doi: 10.1586/17474086.2016.1126176. Epub 2015 Dec 19.
7
Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload.地拉罗司在铁过载的成人中表现出剂量依赖性的肝脏铁减少。
Eur J Haematol. 2019 Aug;103(2):80-87. doi: 10.1111/ejh.13244. Epub 2019 May 30.
8
Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.每日交替使用地拉罗司和去铁酮疗法成功控制了无法治疗的输血依赖型地中海贫血患者的铁蓄积。
Am J Hematol. 2018 Oct;93(10):E338-E340. doi: 10.1002/ajh.25222. Epub 2018 Aug 14.
9
Deferasirox and children: From clinical trials to the real world.地拉罗司与儿童：从临床试验到现实世界
Am J Hematol. 2016 Jun;91(6):E304-5. doi: 10.1002/ajh.24353. Epub 2016 Apr 13.
10
Comparison of Yearly Cost Related to Complications Between Deferasirox and Deferiprone Monotherapy in Thalassemia.地拉罗司与地拉罗酮单药治疗地中海贫血相关并发症的年费用比较。
J Pediatr Hematol Oncol. 2024 Aug 1;46(6):e402-e405. doi: 10.1097/MPH.0000000000002894. Epub 2024 Jun 4.

引用本文的文献

1
[Guidelines for iron chelation therapy in thalassemia in China (2025)].《中国地中海贫血铁螯合治疗指南（2025年版）》
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Apr 15;27(4):377-388. doi: 10.7499/j.issn.1008-8830.2411001.
2
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.地拉罗司治疗患者的严重中性粒细胞减少症和感染风险率：28 年的数据。
Blood Adv. 2024 Nov 12;8(21):5641-5649. doi: 10.1182/bloodadvances.2023012316.
3
Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias.诱导胎儿血红蛋白生成以减少非输血依赖型β-地中海贫血的输血。
Cochrane Database Syst Rev. 2023 Jan 13;1(1):CD013767. doi: 10.1002/14651858.CD013767.pub2.
4
Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.单中心回顾性研究口服铁螯合剂地拉罗司和去铁酮的疗效和毒性。
PLoS One. 2019 Feb 27;14(2):e0211942. doi: 10.1371/journal.pone.0211942. eCollection 2019.
5
Predicting factors for liver iron overload at the first magnetic resonance in children with thalassaemia major.预测重型地中海贫血患儿首次磁共振检查时肝脏铁过载的因素。
Blood Transfus. 2019 May;17(3):165-170. doi: 10.2450/2018.0092-18. Epub 2018 Jun 26.

本文引用的文献

1
Safety profiles of iron chelators in young patients with haemoglobinopathies.血红蛋白病年轻患者中铁螯合剂的安全性概况。
Eur J Haematol. 2017 Mar;98(3):198-217. doi: 10.1111/ejh.12833. Epub 2017 Jan 19.
2
Deferiprone-induced agranulocytosis: 20 years of clinical observations.去铁酮诱导的粒细胞缺乏症：20年临床观察
Am J Hematol. 2016 Oct;91(10):1026-31. doi: 10.1002/ajh.24479. Epub 2016 Aug 4.
3
Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.口服铁螯合剂去铁酮在中国依赖输血的地中海贫血儿童中的安全性概况
Curr Drug Saf. 2016;11(2):137-44. doi: 10.2174/1574886310666150930113957.
4
Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.在临床实践中，偏离地拉罗司治疗的安全指南可能与粒细胞缺乏症风险的增加无关。
Pediatr Blood Cancer. 2014 May;61(5):879-84. doi: 10.1002/pbc.24920. Epub 2013 Dec 30.
5
Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.轻度中性粒细胞减少症患者继续使用去铁酮治疗可能不会导致中性粒细胞计数出现更严重的下降。
Eur J Haematol. 2014 Apr;92(4):337-40. doi: 10.1111/ejh.12241. Epub 2014 Jan 30.
6
Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.去铁酮（GPO-L-ONE(®)）单药治疗可降低输血依赖型地中海贫血患者的铁过载：来自泰国的多中心前瞻性、单臂、开放标签、剂量递增 III 期儿科研究（GPO-L-ONE；A001）的 1 年结果。
Am J Hematol. 2013 Apr;88(4):251-60. doi: 10.1002/ajh.23386. Epub 2013 Mar 5.
7
The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.去铁酮液体制剂在患有输血性铁过载的幼儿中的安全性、耐受性和疗效。
J Pediatr Hematol Oncol. 2010 Nov;32(8):601-5. doi: 10.1097/MPH.0b013e3181ec0f13.
8
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.一项使用心血管磁共振评估去铁胺与去铁酮联合治疗对重型地中海贫血患者心肌铁影响的随机、安慰剂对照、双盲试验。
Circulation. 2007 Apr 10;115(14):1876-84. doi: 10.1161/CIRCULATIONAHA.106.648790. Epub 2007 Mar 19.
9
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.接受去铁胺或去铁酮治疗的重型地中海贫血患者的心脏发病率和死亡率。
Blood. 2006 May 1;107(9):3733-7. doi: 10.1182/blood-2005-07-2933. Epub 2005 Dec 22.
10
Deferiprone, efficacy and safety.
Indian J Pediatr. 2004 Mar;71(3):213-6. doi: 10.1007/BF02724272.